The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of dasatanib (BMS 354825) in recurrent or metastatic ckit-expressing adenoid cystic (ACC) and non-ACC malignant salivary glands tumors (MSGT).
Stuart J. Wong
No relevant relationships to disclose
Ezra E.W. Cohen
No relevant relationships to disclose
Theodore Karrison
No relevant relationships to disclose
David N. Hayes
No relevant relationships to disclose
Merrill S. Kies
No relevant relationships to disclose
Kevin J. Cullen
No relevant relationships to disclose
Tawee Tanvetyanon
No relevant relationships to disclose
Athanassios Argiris
No relevant relationships to disclose
Naoko Takebe
No relevant relationships to disclose
Dean Lim
No relevant relationships to disclose
Nabil F. Saba
No relevant relationships to disclose
Francis P. Worden
No relevant relationships to disclose
Jill Gilbert
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose
Albiruni R.A. Razak
No relevant relationships to disclose
John D. Roberts
No relevant relationships to disclose
Everett E. Vokes
No relevant relationships to disclose